ID   CMK-11-5
AC   CVCL_0217
SY   CMK 11-5; CMK11-5; CMK115
DR   MCCL; MCC:0000106
DR   BioSample; SAMN10987844
DR   cancercelllines; CVCL_0217
DR   Cell_Model_Passport; SIDM01235
DR   DepMap; ACH-001036
DR   GEO; GSM886937
DR   GEO; GSM888003
DR   IARC_TP53; 28399
DR   JCRB; IFO50430
DR   PharmacoDB; CMK115_211_2019
DR   Progenetix; CVCL_0217
DR   Wikidata; Q54813771
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=1391807;
RX   PubMed=1991165;
RX   PubMed=16778363;
RX   PubMed=22460905;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=32180119;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Population: Japanese.
CC   Doubling time: ~2 days (Note=Lot 12122008), ~34 hours (Note=Lot 12082016) (JCRB=IFO50430).
CC   Sequence variation: Gene fusion; HGNC; 4024; FXR2 + HGNC; 11998; TP53; Name(s)=TP53-FXR2 (PubMed=16778363).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp49His (c.145G>C); ClinVar=VCV000135948; Zygosity=Heterozygous (PubMed=16778363).
CC   Omics: Deep exome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0.58%; Native American=0%; East Asian, North=95.47%; East Asian, South=0%; South Asian=0%; European, North=0%; European, South=3.94% (PubMed=30894373).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
ST   Source(s): JCRB
ST   Amelogenin: X,Y
ST   CSF1PO: 11,13
ST   D13S317: 11
ST   D16S539: 9,11
ST   D5S818: 11,12
ST   D7S820: 11,12
ST   TH01: 7
ST   TPOX: 9,11
ST   vWA: 18
DI   NCIt; C2993; Down syndrome
DI   NCIt; C43223; Myeloid leukemia associated with Down syndrome
DI   ORDO; Orphanet_870; Down syndrome
DI   ORDO; Orphanet_99887; Acute megakaryoblastic leukemia in Down syndrome
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_2804 ! CMK-86
SX   Male
AG   10M
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 25
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=1391807;
RA   Nagano T., Ohga S., Kishimoto Y., Kimura T., Yasunaga K., Adachi M.,
RA   Ryo R., Sato T.;
RT   "Ultrastructural analysis of platelet-like particles from a human
RT   megakaryocytic leukemia cell line (CMK 11-5).";
RL   Int. J. Hematol. 56:67-78(1992).
//
RX   PubMed=1991165; DOI=10.1182/blood.V77.3.481.481;
RA   Sakaguchi M., Sato T., Groopman J.E.;
RT   "Human immunodeficiency virus infection of megakaryocytic cells.";
RL   Blood 77:481-485(1991).
//
RX   PubMed=16778363; DOI=10.1620/tjem.209.169;
RA   Kanezaki R., Toki T., Xu G., Narayanan R., Ito E.;
RT   "Cloning and characterization of the novel chimeric gene p53/FXR2 in
RT   the acute megakaryoblastic leukemia cell line CMK11-5.";
RL   Tohoku J. Exp. Med. 209:169-180(2006).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=32180119; DOI=10.1007/s12185-020-02853-6;
RA   Saito H., Hayakawa M., Kamoshita N., Yasumoto A., Suzuki-Inoue K.,
RA   Yatomi Y., Ohmori T.;
RT   "Establishment of a megakaryoblastic cell line for conventional
RT   assessment of platelet calcium signaling.";
RL   Int. J. Hematol. 111:786-794(2020).
//